Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor

US Patent 8338456 · Granted Dec 25, 2012

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dosage regimes for the administration of an anti-CD19 ADC2024
Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein2023
Combination therapy with an anti-CD25 antibody-drug conjugate2023
Dosage regimes for the administration of an anti-CD25 ADC2022
Dosage regimes for the administration of an anti-CD19 ADC2022
Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-2722020
Antineoplastic combinations containing HKI-272 and vinorelbine2018
Antineoplastic combinations containing HKI-272 and vinorelbine2016
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine2016
Treatment regimen utilizing neratinib for breast cancer2015
Anti-tumor activity of CCI-779 in papillary renal cell cancer2014
Anti-tumor activity of CCI-779 in papillary renal cell cancer2014